Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The percent of class is calculated based upon 51,348,656 Common Shares outstanding as of April 17, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on April 17, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percent of class is calculated based upon 51,348,656 Common Shares outstanding as of April 17, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on April 17, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percent of class is calculated based upon 51,348,656 Common Shares outstanding as of April 17, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on April 17, 2025.


SCHEDULE 13G



 
Endeavour Medtech Growth II LP
 
Signature:/s/ Nick Barton
Name/Title:Nick Barton, Director of Endeavour Medtech II GP Limited, its General Partner
Date:05/15/2025
 
Endeavour Medtech Growth II Parallel LP
 
Signature:/s/ Nick Barton
Name/Title:Nick Barton, Director of Endeavour Medtech II GP Limited, its General Partner
Date:05/15/2025
 
Endeavour Medtech II GP Limited
 
Signature:/s/ Nick Barton
Name/Title:Nick Barton, Director
Date:05/15/2025

Comments accompanying signature:  Exhibit A Joint Filing Agreement, dated as of May 15, 2025